目的 运用Meta分析方法评价肾康注射液治疗慢性肾衰竭的疗效。方法 通过检索中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、中文科技期刊全文数据库(维普)、万方数字化期刊全文库等数据库,对纳入的随机对照试验文献进行质量评价,并采用Rev Man 5.2软件进行Meta分析。结局指标为血尿素氮(BUN)、血肌酐(Scr)和肌酐清除率(Ccr)。结果 共纳入16篇随机对照试验,共1 064名患者。Meta分析结果显示,肾康注射液能显著降低BUN[WMD=-3.45,95%CI(-5.72,-1.18),P < 0.01]和Scr[WMD=-0.77,95%CI(-1.16,-0.38),P < 0.01],提高Ccr方面与对照组无统计学意义[WMD=0.25,95%CI(-0.32,0.83)]。结论 肾康注射液能显著降低BUN和Scr,但本研究纳入的文献质量较低,期待更多大样本、高质量的随机对照实验。

Objective To evaluate the efficacy of Shenkang Injection in treatment of chronic renal failure by Meta analysis. Methods By searching Chinese biomedical literature database (CBM), China Journal Full-text Database (CNKI), Chinese Science and Technology Journal Full-text Database (VIP), and Wanfang Database, etc, the quality assessment of qualified randomly control trials was evaluated. Meta analysis was carried out by Rev Man 5.2 software. The outcomes included blood urea nitrogen (BUN), serum creatinine (Scr), and creatinine clearance rate (Ccr). Results A total of 16 studies were included, involving 1064 patients. Meta analysis showed that ShenKang Injection could significantly decrease in BUN [MD = -3.45, 95%CI (-5.72, -1.18), P < 0.01] and Scr [MD = -0.77, 95%CI (-1.16, -0.38)]. There was no significantly increase in Ccr [MD = 0.25, 95%CI (-0.32, 0.83)]. Conclusion Shenkang Injection can decrease BUN and Scr. But the quality of included studies is low, more high quality of randomized trails are expected.